EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis

Zeyu Shi, Margarita Artemenko, Weiyu Yu, Ming Zhang, Canhui Yi, Peng Chen, Shuting Lin, Zhancun Bian, Baoping Lian, Fanzhen Meng, Jiaxuan Chen iD, Tom Roussel und 8 weitere

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.4c12857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Zeyu Shi und 19 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 999077, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Imatinib Mesylate, beta Catenin, Dendrimers. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health and Medical Research Fund, Innovation and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the leading cause of death among all gynecological malignancies, and drug resistance renders the current chemotherapy agents ineffective for patients with advanced metastatic tumors. We report an effective treatment strategy for targeting metastatic ovarian cancer involving a nanoformulation (Bola/IM)─bola-amphiphilic dendrimer (Bola)-encapsulated imatinib (IM)─to target the critical mediator of ovarian cancer stem cells (CSCs) CD117 (c-Kit). Bola/IM offered significantly more effective targeting of CSCs compared to IM alone, through a novel and tumor-specific β-catenin/HRP2 axis, allowing potent inhibition of cancer cell survival, stemness, and metastasis in metastatic and drug-resistant ovarian cancer cells. Promising results were also obtained in clinically relevant patient-derived ascites and organoids alongside high tumor-oriented accumulation and favorable pharmacokinetic properties in mouse models. Furthermore, Bola/IM displayed synergistic anticancer activity when combined with the first-line chemotherapeutic drug cisplatin in patient-derived xenograft mouse models without any adverse effects. Our findings support the use of Bola/IM as a nanoformulation to empower IM, providing targeted and potent treatment of metastatic ovarian cancer. Our study thus represents a significant advancement toward addressing the unmet medical need for improved therapies targeting this challenging disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsImatinib Mesylatebeta CateninDendrimersAntineoplastic AgentsFemaleHumansAnimalsMiceCell Line, TumorSignal TransductionXenograft Model Antitumor AssaysNeoplastic Stem Cells

Stichwörter der Autor:innen

cancer stem cellschemoresistancedendrimernanovectorovarian cancertargeted therapy

Substanzen

Imatinib Mesylatebeta CateninDendrimersAntineoplastic Agents

Autor:innen und Institutionen

  • School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 999077, China.
  • Laboratory for Synthetic Chemistry and Chemical Biology Limited, Pokfulam, Hong Kong 999077, China.
  • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China.
  • Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille, Equipe Labellisée Ligue Contre le Cancer, 13288 Marseille, France.
  • Department of Obstetrics and Gynecology, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong 999077, China.
  • Department of Pathology, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong 999077, China.

ORCID-Profile: Jiaxuan Chen, Ling Peng, Alice S T Wong

Förderung

  • Health and Medical Research Fund
  • Innovation and Technology Commission

Zitieren

APA

Shi, Z., Artemenko, M., Yu, W., Zhang, M., Yi, C., Chen, P., Lin, S., Bian, Z., Lian, B., Meng, F., Chen, J., Roussel, T., Li, Y., Chan, K. K. L., Ip, P. P. C., Lai, H. C., To, S. K. Y., Liu, X., Peng, L., & Wong, A. S. T. (2025). Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c12857

Vancouver

Shi Z, Artemenko M, Yu W, Zhang M, Yi C, Chen P, et al. Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c12857

BibTeX
@article{Shi2025,
  author = {Shi, Zeyu and Artemenko, Margarita and Yu, Weiyu and Zhang, Ming and Yi, Canhui and Chen, Peng and Lin, Shuting and Bian, Zhancun and Lian, Baoping and Meng, Fanzhen and Chen, Jiaxuan and Roussel, Tom and Li, Ying and Chan, Karen K L and Ip, Philip P C and Lai, Hung-Cheng and To, Sally K Y and Liu, Xiaoxuan and Peng, Ling and Wong, Alice S T},
  title = {Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.4c12857}
}
Kostenlos starten →